Sandra Xavier

Followers

Following

Co-authors

Public Views

Karim N'Diaye

Centre National de la Recherche Scientifique / French National Centre for Scientific Research

Jason Hassenstab

Washington University in St. Louis

Andreas Kotsakis

University of Kent

Susana O Dias

Universidade Estadual de Campinas

Francisco Paulo Jamil Marques

The University of Iowa

Karl Stephen

Heriot-Watt University

Juliano M Carvalho

Universidade Estadual Paulista "Júlio de Mesquita Filho"

Alessandra Aldé

UERJ - Universidade do Estado do Rio de Janeiro / Rio de Janeiro State University

Antonio Santamaria

CSIC (Consejo Superior de Investigaciones Científicas-Spanish National Research Council)

Paolo Davide Farah

West Virginia University

Interests

Uploads

Papers by Sandra Xavier

Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using Alemtuzumab and Cyclophosphamide as Conditioning Regimen

Blood

3198 Poster Board III-135 Introduction Cyclophosphamide (Cy) with/without antithymocyte globulin ... more 3198 Poster Board III-135 Introduction Cyclophosphamide (Cy) with/without antithymocyte globulin (ATG) as conditioning regimen for allogeneic hematopoietic stem cell transplantation (AlloHSCT) is the treatment of choice for young patients with severe aplastic anemia (SAA). In developing countries, and particularly in Brazil, ATG costs limit its use in AlloHSCT for SAA patients. Alternative low-cost regiments, like busulfan (BU) with Cy as conditioning regimen is still associated with a significant rate of rejection, especially in heavily transfused patients, and long-term infertility. Alemtuzumab (Cam) was reported as an alternative to ATG for SAA patients, with similar activity and a lower cost. Material and Methods In order to study the effect of the combination of Cy and Cam, we reviewed all AlloHSCT performed for SAA using this conditioning regimen. Between April 2007 and Mai 2009, fifteen patients with SAA (defined by Camitta criteria) underwent an AlloHSCT in our institution. ...

Comparison between flow cytometry and standard PCR in the evaluation of MRD in children with acute lymphoblastic leukemia treated with the GBTLI LLA – 2009 protocol

Pediatric Hematology and Oncology

Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience

Leukemia research, Sep 1, 2017

Current results regarding treatment outcomes in acute myeloid leukemia (AML) point to significant... more Current results regarding treatment outcomes in acute myeloid leukemia (AML) point to significant differences between low- and middle-income countries (LMIC) and high-income countries (HIC). Excluding well-known socioeconomic issues, genetic markers important for prognosis have not been properly incorporated into the clinical practice so far and their usefulness outside of well-controlled clinical trials remain unknown. Here, we assessed the clinical significance of the European LeukemiaNet (ELN) recommendations in 196 consecutive patients with AML in a real-life setting. All patients were younger than 60 years of age (49% male) and treated with conventional chemotherapy for induction and consolidation in three Brazilian Institutions that well represent Brazilian geographic and socioeconomic diversity. Multivariable analysis showed that ELN recommendations had a slight association with complete remission achievement (odds ratio: 0.74, 95% confidence interval, CI: 0.53-1.01; P=0.06),...

Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia

Mediterranean Journal of Hematology and Infectious Diseases, 2016

Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Current treatment strat... more Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Current treatment strategies for childhood ALL result in long term remission for approximately 90% of patients. However, therapeutic response is worse among those who relapse. Several risk stratification approaches based on clinical and biological aspects have been proposed in order to intensify treatment in patients with high risk of relapse and reduce toxicity on those with greater probability of cure.The detection of residual leukemic cells (minimal residual disease, MRD) is the most important prognostic factor to identify high risk patients, allowing redefinition of chemotherapy. In the last decades, several standardized research protocols evaluated MRD using immunophenotyping by flow cytometry and/or real time quantitative polymerase chain reaction at different time points during treatment. Both methods are highly sensitive (10-3 a 10-5), but expensive, complex, and, because of that, require qualified sta...

Sandra Xavier

Uploads

Papers by Sandra Xavier

Log In